NO20085140L - Nye indazolderivater som har spiro ringstruktur i sidekjede - Google Patents

Nye indazolderivater som har spiro ringstruktur i sidekjede

Info

Publication number
NO20085140L
NO20085140L NO20085140A NO20085140A NO20085140L NO 20085140 L NO20085140 L NO 20085140L NO 20085140 A NO20085140 A NO 20085140A NO 20085140 A NO20085140 A NO 20085140A NO 20085140 L NO20085140 L NO 20085140L
Authority
NO
Norway
Prior art keywords
represent
side chain
derivative
halogen
ring structure
Prior art date
Application number
NO20085140A
Other languages
English (en)
Inventor
Masahiko Hagihara
Atsushi Shimazaki
Takeshi Matsugi
Yasunori Tsuzaki
Hiroshi Nishida
Ken-Ichi Komori
Kazutaka Kido
Tomokazu Fujimoto
Original Assignee
Ube Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ube Industries filed Critical Ube Industries
Publication of NO20085140L publication Critical patent/NO20085140L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)

Abstract

Et formål med foreliggende oppfinnelse er å tilveiebringe et nytt indazolderivat som har en spiroringstruktur i en sidekjede, hvilket derivat er nyttig som et farmasøytisk preparat, samt å finne en ny farmakologisk aktivitet for derivatet. Foreliggende oppfinnelsesforbindelse er representert ved den generelle formelen (I) og har en utmerket Rho-kinaseinhiberende aktivitet. I formelen representerer ringen X en benzenring eller en pyridinring; R1 og R2 representerer et halogen, H, OH, alkoksy, cykoalkyloksy, aryloksy, alkyl, cykloalkyl eller lignende; R3 representerer halogen, H eller lignende; R4 og R5 representerer halogen, H eller lignende; R6 og R7 representerer H, alkyl eller lignende; og m, n, p og q representerer et heltall på 0 til 3. I denne sammenheng kan hver gruppe ha en substituent. (I)
NO20085140A 2006-06-08 2008-12-10 Nye indazolderivater som har spiro ringstruktur i sidekjede NO20085140L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006159501 2006-06-08
PCT/JP2007/061598 WO2007142323A1 (ja) 2006-06-08 2007-06-08 側鎖にスピロ環構造を有する新規インダゾール誘導体

Publications (1)

Publication Number Publication Date
NO20085140L true NO20085140L (no) 2009-03-06

Family

ID=38801567

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20085140A NO20085140L (no) 2006-06-08 2008-12-10 Nye indazolderivater som har spiro ringstruktur i sidekjede

Country Status (10)

Country Link
US (1) US8227480B2 (no)
EP (1) EP2025676A4 (no)
JP (1) JPWO2007142323A1 (no)
KR (1) KR20090026264A (no)
CN (1) CN101460477A (no)
CA (1) CA2653424A1 (no)
NO (1) NO20085140L (no)
RU (1) RU2008152065A (no)
TW (1) TW200815398A (no)
WO (1) WO2007142323A1 (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007008926A1 (en) 2005-07-11 2007-01-18 Aerie Pharmaceuticals, Inc. Isoquinoline compounds
WO2008036540A2 (en) 2006-09-20 2008-03-27 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
US8455514B2 (en) 2008-01-17 2013-06-04 Aerie Pharmaceuticals, Inc. 6-and 7-amino isoquinoline compounds and methods for making and using the same
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
EP3053913B1 (en) 2009-05-01 2018-03-07 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
CA2799154A1 (en) 2010-05-12 2011-11-17 Abbvie Inc. Indazole inhibitors of kinase
TWI476188B (zh) 2010-05-27 2015-03-11 Ube Industries 新穎吲唑衍生物或其鹽及其製造中間體、以及使用其之抗氧化劑
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
JP6064062B2 (ja) 2013-03-15 2017-01-18 ファイザー・インク Ａｍｐｋを活性化させるインダゾール化合物
DK3811943T3 (da) 2013-03-15 2023-04-03 Aerie Pharmaceuticals Inc Forbindelse til anvendelse til behandling af øjenlidelser
US9902702B2 (en) 2014-07-15 2018-02-27 Bristol-Myers Squibb Company Spirocycloheptanes as inhibitors of rock
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
US10550087B2 (en) 2015-11-17 2020-02-04 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
TWI730032B (zh) * 2016-01-13 2021-06-11 美商必治妥美雅史谷比公司 作為ｒｏｃｋ抑制劑之螺庚烷水楊酸醯胺及相關化合物
KR102568079B1 (ko) 2016-08-31 2023-08-17 에어리 파마슈티컬즈, 인코포레이티드 안과용 조성물
KR20190135027A (ko) 2017-03-31 2019-12-05 에어리 파마슈티컬즈, 인코포레이티드 아릴 시클로프로필-아미노-이소퀴놀리닐 아미드 화합물
US20200121652A1 (en) 2017-06-16 2020-04-23 The Doshisha Compounds having caspase inhibitory activity, pharmaceutical agent containing said compounds and for treating or preventing corneal endothelial symptoms, disorders, or diseases, and application of said pharmaceutical agent
EP3639854B1 (en) 2017-06-16 2026-01-07 The Doshisha Mtor-inhibitor-containing medicine for treating or preventing fuchs' endothelial corneal dystrophy
TW201908293A (zh) * 2017-07-12 2019-03-01 美商必治妥美雅史谷比公司 作為rock抑制劑之5員及雙環雜環醯胺
US11447487B2 (en) 2017-07-12 2022-09-20 Bristol-Myers Squibb Company Spiroheptanyl hydantoins as rock inhibitors
US12060341B2 (en) 2017-07-12 2024-08-13 Bristol-Myers Squibb Company Spiroheptanyl hydantoins as ROCK inhibitors
US10399944B2 (en) 2017-08-10 2019-09-03 Janssen Pharmaceutica Nv Pyridin-2-one derivatives of formula (III) useful as EP3 receptor antagonists
US10590083B2 (en) 2017-08-10 2020-03-17 Janssen Pharmaceutica Nv Pyridin-2-one derivatives of formula (I) useful as EP3 receptor antagonists
US10336701B2 (en) 2017-08-10 2019-07-02 Janssen Pharmaceutica Nv Pyridin-2-one derivatives of formula (II) useful as EP3 receptor antagonists
AU2019337703B2 (en) 2018-09-14 2023-02-02 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
CN114369082B (zh) * 2022-02-28 2023-09-05 贵州大学 吡啶取代螺环类化合物及其在制备抗植物病毒剂中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT868186E (pt) 1995-12-21 2005-05-31 Alcon Lab Inc Utilizacao de certos compostos de isoquinolinossulfonilo para tratamento de glaucoma e isquemia ocular
NZ513800A (en) 1996-08-12 2001-09-28 Welfide Corp Treatment of diseases using Rho kinase inhibitors
JP4212149B2 (ja) 1998-06-11 2009-01-21 株式会社デ・ウエスタン・セラピテクス研究所 医薬
AU5198199A (en) 1998-08-17 2000-03-06 Senju Pharmaceutical Co., Ltd. Preventives/remedies for glaucoma
WO2000057914A1 (en) 1999-03-25 2000-10-05 Santen Pharmaceutical Co., Ltd. Ocular tension-lowering agents
US7217722B2 (en) 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
MXPA03008659A (es) * 2001-03-23 2005-04-08 Bayer Ag Inhibidores de rho-cinasa.
US20030125344A1 (en) * 2001-03-23 2003-07-03 Bayer Corporation Rho-kinase inhibitors
JPWO2002100833A1 (ja) * 2001-06-12 2004-09-24 住友製薬株式会社 Ｒｈｏキナーゼ阻害剤
AR037754A1 (es) 2001-12-11 2004-12-01 Syngenta Participations Ag Herbicidas
EP2468729B1 (en) * 2003-10-15 2013-12-25 Ube Industries, Ltd. Novel indazole derivative
US7592357B2 (en) 2004-02-20 2009-09-22 Smithkline Beecham Corporation Compounds
WO2005080394A1 (en) * 2004-02-24 2005-09-01 Bioaxone Therapeutique Inc. 4-substituted piperidine derivatives

Also Published As

Publication number Publication date
KR20090026264A (ko) 2009-03-12
JPWO2007142323A1 (ja) 2009-10-29
RU2008152065A (ru) 2010-07-20
EP2025676A1 (en) 2009-02-18
EP2025676A4 (en) 2011-06-15
CN101460477A (zh) 2009-06-17
US20090170887A1 (en) 2009-07-02
US8227480B2 (en) 2012-07-24
CA2653424A1 (en) 2007-12-13
WO2007142323A1 (ja) 2007-12-13
TW200815398A (en) 2008-04-01

Similar Documents

Publication Publication Date Title
NO20085140L (no) Nye indazolderivater som har spiro ringstruktur i sidekjede
NO20080717L (no) Oksimderivat og fremgangsmate for fremstilling av dette
NO20092770L (no) Nye aminopyrimidinderivater som PLK1-inhibitorer
NO20092415L (no) Heteromonocyklisk forbindelse og anvendelse derav
NO20062988L (no) Sykliske aminderivater med heteroarylring
EP2017278A4 (en) DIHYDROPYRAZOLOPYRIMIDINONDERIVAT
NO20084583L (no) Makrosykliske kinase-inhibitorer
NO20076524L (no) Pyrazolforbindelse samt terapeutisk middel for diabetes som omfatter det samme
NO20090760L (no) Nye tricykliske spiropiperidinforbindelser, deres synteser og deres anvendelser som modulatorer av kemokinreseptor-aktivitet
NO20063446L (no) Tiazolderivater
NO20080981L (no) Nitrocatechol-derivater som COMT-inhibitorer
NO20085107L (no) Spirosykliske nitriler som proteaseinhibitorer
WO2009054439A1 (ja) Pai-1産生抑制剤
MX2009011769A (es) Derivados de piridona como inhibidores de mapk p38a.
NO20080779L (no) Nye farmasoytiske forbindelser
NO20082975L (no) Nye cykliske ureaderivater, fremstilling derav og farmasoytisk anvendelse derav som kinaseinhibitorer
WO2008105408A1 (ja) ウレイド基とアミノカルボニル基を置換基として有する新規ピロール誘導体
NO20071254L (no) Fremgangsmate for fremstilling av irbesartan og mellomprodukter derav.
NO20060142L (no) Syklisk tertiaer aminforbindelse
WO2010003084A3 (en) Phosphodiesterase 4 inhibitors
EP2036905A4 (en) Pyridylisoxazole derivative
MY161992A (en) Novel tetrahydroisoquinoline derivative
NO20081220L (no) Nytt cercosporamidderivat
PH12013500443A1 (en) Heterocyclic compounds for treating or preventing disorders caused by reduced neurotransmission of serotonin, norephnephrine or dopamine.
BR112016009811A2 (pt) derivado de carboximetil piperidina

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application